Zai Lab (NASDAQ:ZLAB) was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a research report issued to clients and investors on Wednesday, January 10th.
ZLAB has been the topic of a number of other reports. JPMorgan Chase & Co. initiated coverage on Zai Lab in a research note on Monday, October 16th. They set a “neutral” rating and a $32.00 price objective on the stock. Leerink Swann assumed coverage on Zai Lab in a research note on Monday, October 16th. They issued an “outperform” rating and a $42.00 target price on the stock. Finally, Citigroup assumed coverage on Zai Lab in a research note on Monday, October 16th. They issued a “buy” rating on the stock.
Zai Lab (NASDAQ:ZLAB) opened at $25.35 on Wednesday. Zai Lab has a 12 month low of $20.67 and a 12 month high of $35.74.
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. FNY Partners Fund LP purchased a new stake in Zai Lab in the third quarter worth about $137,000. Pinebridge Investments L.P. purchased a new stake in Zai Lab in the third quarter worth about $945,000. Finally, Gilder Gagnon Howe & Co. LLC lifted its holdings in Zai Lab by 64.9% in the fourth quarter. Gilder Gagnon Howe & Co. LLC now owns 917,123 shares of the company’s stock worth $19,471,000 after buying an additional 360,801 shares during the period. 18.14% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: “Zai Lab (ZLAB) Rating Increased to Sell at BidaskClub” was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this article on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2018/02/06/zai-lab-zlab-raised-to-sell-at-bidaskclub.html.
About Zai Lab
Zai Lab Ltd, incorporated on March 28, 2017, is a biopharmaceutical company. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including in the fields of oncology, autoimmune and infectious diseases.
Receive News & Ratings for Zai Lab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zai Lab and related companies with MarketBeat.com's FREE daily email newsletter.